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Objective
PD-L1 is an immune checkpoint molecule expressed by
a variety of tumors, including ovarian, which binds to
circulating PD-1 expressing effector T cells allowing for
tumor escape from the immune system. PD-L1 blockade
prevents PD-L1/PD-1 interaction and is currently
explored as therapy of solid tumors. Ovarian cancer
patients receive combination cisplatin/taxane che-
motherapy as standard of care. Chemo-induced effects on
tumor PD-L1 expression have been only partially
addressed. We studied here the effect of platinum/taxane
exposure on PD-L1 expression in vitro and in vivo.
Methods
Human (OVCA 420 and OVCA432) and mouse (2F8)
ovarian cancer cell lines were exposed to increasing doses
of cisplatin and paclitaxel for different time periods.
PD-L1 expression was analyzed with flow cytometry and
Western blot. Through continuous exposure in vitro of
mouse 2F8 ovarian cancer cells to increasing doses of cis-
platin we have derived a new cisplatin-resistant line (2F8-
Cis). In vivo, we have challenged n=37 mice IP with 0.8
million 2F8 cells. Tumor-bearing mice were treated with
cisplatin, anti-PD-L1 antibody, both drugs, or isotype
control every two weeks for three doses starting at day
14 post-inoculation. Tumor- and ascites-derived cancer
cells were analyzed with flow cytometry.
Result
Exposure of OVCA420 and OVCA432 to cytotoxic doses
of cisplatin or paclitaxel trigger PD-L1 up-regulation.
Similarly, 2F8-Cis cells show increased cell surface PD-L1
compared to parental 2F8 cells, providing the rationale
for combination therapy with PD-L1 blockade. In vivo
treatment of mice with aggressive 2F8 tumors respond
well to cisplatin and anti-PD-L1 individually with
increased survival (median 45 days versus 24 days for iso-
type control, p=0011). At necropsy, anti-PD-L1 therapy
significantly reduced tumor burden (1.48 g versus 0.25 g,
p=0.0294). Tumor cells cultured from cisplatin-only trea-
ted mice expressed higher levels of PD-L1, in line with
our in vitro results. A higher percentage of PD-1 expres-
sing cells were found amongst the tumor cells in these
cultures versus cisplatin/anti-PD-L1 treated mice.
Although high dose anti-PD-L1 immediately following
cisplatin administration can control tumor burden
(0.48 g), it does not significantly prolong survival (median
29 days). We are currently testing an alternative thera-
peutic schema exploring a lower anti-PD-L1 dose and a
different timing post-chemo.
Conclusion
Tumor cells upregulate PD-L1 in response to chemother-
apy exposure and combination PD-L1 blockade in con-
junction with chemotherapy effectively controls tumor
burden. Optimization of timing and dosage for this combi-
nation therapy will likely increase its therapeutic benefit.
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